Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Leukemia 2 Triple Negative Breast Neoplasms 1 Peritoneal Neoplasms 1 Ovarian Neoplasms 1 Ovarian Cancer Recurrent 1 Neoplasm Metastasis 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Influenza, Human 1 Hematologic Neoplasms 1 Colorectal Neoplasms 1

Interventions

Carboplatin 46 Paclitaxel 31 pembrolizumab 25 Cyclophosphamide 24 Nivolumab 14 Bevacizumab 14 Topotecan 12 Gemcitabine 12 liposomal doxorubicin 11 Filgrastim 11 Cisplatin 11 fludarabine 10 Peripheral Blood Stem Cell Transplantation 10 olaparib 8 aldesleukin 7 durvalumab 6 Oxaliplatin 6 Ipilimumab 6 Interleukin-2 6 Docetaxel 6 niraparib 5 epacadostat 5 cemiplimab 5 Ifosfamide 5 Fulvestrant 5 rucaparib 4 poly ICLC 4 pazopanib 4 avelumab 4 atezolizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Neoplasms × Interferon alpha-2 × Clear all

NCT01639885 2014-01-07

CHIP

Leiden University Medical Center

Phase 1/2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡